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ABSTRACT

A possible insulin-independent regulatory mechanism of

hepatic ketogenesis was studied in eight experiments on five
ewes

surgically

catheterized

in

hepatic,

portal,

and

mesenteric veins, and femoral artery and femoral vein.

Ewes

were made diabetic with alloxan (50 mg/kg bw, iv). Euglycemia
was maintained with daily insulin injections (Iletin-100 «-35
lU/d)

until

three

days

prior

to

each

experiment,

injections were withheld to induce ketosis.

when

Ewes were housed

in 1.8 X 3.0 m indoor pens under natural lighting in a
thermoneutral environment.

infusion

periods:

(1)

Experiments consisted of three

para-aminohippurate

(1.5%

@

0.764

ml/min) infusion into the common mesenteric vein (control);

(2) para-aminohippurate as in (1) and beta-hydroxybutyrate
(1.18 mmol/min) into the common mesenteric vein; and (3) para-

aminohippurate

and

beta-hydroxybutyrate

as

in

(2)

and

gamma-butyrobetaine (1.18 mmol/min) into the common mesenteric
vein.

For

each

period,

each

infusate

was

allowed

to

equilibrate for one hour and then three blood samples were
taken simultaneously from the hepatic, portal, and femoral
veins and femoral artery at thirty minute intervals
analyzed

for

beta-hydroxybutyrate,

and

acetoacetate,

non-esterified fatty acids, glucose, and para-aminohippurate.
Blood flows were calculated by measuring downstream dilution

of para-aminohippurate and net fluxes were calculated by
multiplying tissue veno-arterial concentrations by tissue

V

blood

flow.

Blood

glucose

(«10

mM)

was

unaffected

by

infusion. Beta-hydroxybutyrate decreased hepatic flow (3.6 to
2.5

L/min,

P<.01),

but

did

not

change

portal

flow.

Consequently, portal flow contribution to the liver increased
from 73 to 83% (P<.01) during beta-hydroxybutyrate infusion.
Relative to control, beta-hydroxybutyrate infusion decreased
(P<.01) non-esterified fatty acid arterial concentrations (2.1

to 1.1 mM)

splanchnic

and hepatic (0.7 to 0.2 mmol/min) and total

(0.6

to

hydroxybutyrate

0.2

mmol/min)

net

uptakes.

infusion

increased

acetoacetate

Betaarterial

concentrations (1.2 to 1.5 mM, P<.05) and decreased

hepatic

release

ketogenesis)
mmol/min).

(0.5

and

to

total

0.1

mmol/min)(i.e.,

splanchnic

release

(P<.05)

decreased

(0.6

to

0.1

Similar to its effects on acetoacetate, beta-

hydroxybutyrate

infusion

increased

beta-hydroxybutyrate

arterial concentrations (7.6 to 12.3 mM, P<.01) but decreased

net hepatic release (1.6 to 0.7 mmol/min, P<.01) and total

splanchnic release (2.1 to 1.3 mmol/min, P<.1).
butyrobetaine
hydroxybutyrate

infusion

did

effects.

not

According

Gamma-

reverse

any

beta-

to

data

beta-

this

hydroxybutyrate may regulate ketogenesis by decreasing hepatic
non-esterified fatty acid uptake and subsequent conversion to
acetoacetate and beta-hydroxybutyrate.

Gamma-butyrobetaine,

in contrast, had no effect on hepatic ketogenesis nor non-

esterified

fatty

hydroxybutyrate

acid

uptake,

inhibition

was

suggesting

not

at

that

the

beta-

carnitine

VI

acyltransferase level or that gamma-butyrobetaine may not be
extracted by the liver in quantities sufficient to counteract

observed effects of beta-hydroxybutyrate.
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CHAPTER I

INTRODUCTION

Hyperketonemia can be a result of starvation, diabetes

mellitus, late gestation or early lactation (18).

It is

described by elevated 'circulating NEFA accompanied by
increased fatty acid utilization and decreased carbohydrate

utilization (20,22).

The stress of late pregnancy or early

lactation induces increased lipolysis, making more NEFA

available to the liver as substrate (19).

Increased hepatic

uptake of NEFA may result in elevated production of ketone

bodies, i.e. beta-hydroxybutyrate and acetoacetate, causing
ketosis (34).

Hepatic production of ketone bodies beyond

extrahepatic utilization results in a buildup of ketone

bodies in the blood (34), marked by lowered blood pH known
as ketoacidosis.

This condition can progress to coma and

death if untreated.

Under fasting conditions, alimentary ketogenesis ceases
and hepatic ketogenesis increases (24).

The ruminant liver

switches from fatty acid reesterification to ketone body
production and fatty acid oxidation during a matter of hours

(34,36,55).

Ketone body concentrations rise more markedly

than any other fuel source during starvation (38).

Ketone

body production accompanied by decreased hepatic glucose
output can result in a 30% reduction in peripheral tissue
uptake of glucose.

In this way protein precursors of

glucose are spared, and glucose is conserved for the brain

2

and other obligatory tissues (30).

Ketones are a very efficient fuel source during periods
of high metabolic demand.

Unlike NEFA, ketones can be

transported in the blood at high concentrations in the free
state.

Due to their toxicity in the free state, NEFA

require an albumin transporter which lowers their diffusion

rate into the cell and limits their availability.

Ketones

can be transported at concentrations high enough to replace
glucose as an energy source (30,38).

Control of ketogenesis occurs at the prehepatic and
hepatic level (34).

Triglycerides in adipose tissue are

broken down by hormone-sensitive lipase, releasing free

fatty acids and glycerol.

The hormones insulin and glucagon

exert a strong influence on hormone-sensitive lipase;
insulin inhibiting its action by dephosphorylation, thereby
limiting the amount of precursor available for hepatic
ketogenesis (34), and glucagon stimulating it via cAMP-

dependent phosphorylation (6,16).

Bjorntorp (7) proposed

that ketones may suppress hormone-sensitive lipase directly.

Drackley (15) proposed that ketone bodies may regulate NEFX
oxidation at a site within the liver.

Ketone bodies may

have an autoregulatory effect on their own production by
stimulating insulin release, which inhibits the release of
free fatty acids from adipose tissue and therefore limits
the amount of substrate available for ketogenesis
(15,19,34,55).

CHAPTER II
LITERATURE REVIEW

Ketone Bodv Production

Free fatty acids are released from adipose tissue and

transported in the blood bound to albumin (38) (Figure 1).
Inside the liver, the acyl unit is activated to an acyl-CoA

by acyl-CoA synthase and ATP.

The acyl-CoA may be

esterified to an acylglycerol and undergo triacylglycerol

synthesis (21), or enter the hepatic mitochondria to undergo
beta-oxidation (34).

Transport across the inner

mitochondrial membrane involves the carnitine

palmitoyltransferase (CPT) mechanism.

Within the matrix,

the acyl-CoA undergoes beta-oxidation to acetyl-CoA, which
is either fully oxidized to CO2 via the tricarboxylic acid
(TCA) cycle, or converted to ketone bodies.
Zammit (55) proposed that the shift from

triacylglyceride synthesis to oxidation during ketogenesis
can be ascribed to a decrease in long-chain fatty acyl-CoA

entering the esterification pathway due to an increase in

acyl-carnitine production.

In fasted rats, mitochondrial

glycerol-3-phosphate acyl-transferase (GPAT) activity
decreased by 40% (55).

This enzyme is responsible for the

union of acyl-CoA and glycerol-3-phosphate in the formation

of triacylglyceride.

Its decreased activity implies a

lowered rate of esterification during starvation.

Starved

Triacvlglycerol

HORMONE-SEN
SITIVE LIPASE

ADIPOSE
TISSUE

t

'Catecholamines

- Glucagon

Co

*lrwulin

FFA

VLDL

BLOOD

Carbohydrate

LIVER

FFA

Acetyl-CoA

Etnrificttion
^-Acyl-CoA ~

Glucagon
Insulin

carboxylase

o

G

Insulin

Glucagon

Malonyl-CoA

Acylglycerols

^

ACETYL-CoA

Cytosol

•»>.
CARNITINE

upogtntsis

PALMITOYt
TRANSFERASE I

Palmitate

Jn.
'ona,
'r/a/

~T~~

■'^6: *0.
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• ^ Katogarmis

Acetyl-CoA

CO,

Katone bodies

Figure 1:

Regulation of long-chain fatty acid oxidation
in the liver. (FFA, free fatty acids; VLDL,
very low density lipoproteins.) (Harper's, 1985)
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rats also exhibited a two to three-fold increase in CPT-I

activity as opposed to fed rats (55), implying an increase

in long-chain fatty acid transport into the mitochondria.
Upon entering the oxidation pathway, the acyl-CoA is
bound reversibly with carnitine by CPT-I, which is loosely
bound to the outer side of the inner mitochondrial membrane,

to become acyl-carnitine (13,34,48) (Figure 2).

Acyl-

carnitine exchanges with free carnitine across the
mitochondrial membrane via carnitine acyl-carnitine
translocase.

Within the matrix, the acylcarnitine is split

i

to the original acyl-CoA and free carnitine by CPT-II on the
inner side of the mitochondrial membrane (13).

The acyl-CoA

is then available to undergo beta-oxidation.

Any inhibition of the CPT transport mechanism effects
the flow of NEFA into ketone bodies (34), and it has been

suggested that this is the rate-limiting step in fatty acid
oxidation (37).

Malonyl-CoA is a strong competitive

inhibitor of CPT-I, but not CPT-II, because of the

impermeability of the inner mitochondrial membrane.

By

binding to CPT-I, malonyl-CoA inhibits acyl-CoA transport
into the matrix.

Declercq et al. (13) proposed that CPT-I

and CPT-II are separate entities, CPT-II being smaller than
CPT-I and showing different sensitivity to inhibitors, such
as malonyl-CoA.

The acyl-CoA unit itself has an inhibitory effect on

acetyl-CoA carboxylase, the enzyme responsible for the

FFA

ATP + CoA
ACYL-CoA
SYNTHETASE

AMP + PP

Acyl-CoA

CoA

Acyl-

Carnitine

carnitine

foutside)

CARNITINE
PALMITOYL
TRANSPERASEI

C side

Inner

mftochorrdrial
membrane

CARNITINEACYLCARNITINE
TRANSLOCASE

CARNITINE

PALVIITOYL

M side

TRANSFERASE II

(inside)

Acyl-

Carnitine

carnitine

Acyl-CoA

CoA

p-Oxidation

Figure 2: Role of carnitine in the transport of
Icpng-chain fatty acids through the inner
mitochondrial membrane (Harper's, 1985).
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conversion of acetyl-CoA to malonyl-CoA.

Increased

concentrations of acyl-CoA decrease malonyl-CoA inhibition

of the CPT-I transport mechanism (35), thereby relieving the
inhibition which may have prevented entrance to the
mitochondria and incorporation of the acyl-CoA into ketone
bodies instead of acylglycerols.
Inside the matrix, the acetyl-CoA required for the

Krebs cycle joins with oxaloacetate to form citrate via
citrate synthase, whereas the excess intramitochondrial

acetyl-CoA combines to form acetoacetyl-CoA (48).

This is

the first committed step in the hydroxymethylglutaryl-CoA

(HMG-CoA) pathway (56).

The reaction is catalyzed by

acetyl-CoA acetyltransferase, which competes with citrate
synthase for acetyl-CoA (56).

Studies suggest that citrate

synthase has a lower K^, for acetyl-CoA within the hepatic
mitochondria than does acetyl-CoA acetyltransferase (56).
If so, rates of ketogenesis are dependent largely upon the
amount of oxaloacetate available to draw acetyl-CoA into the

TCA cycle and away from the ketogenic pathway (2,3).
A close relationship exists between ketogenic rates and
free oxaloacetate concentrations in isolated hepatocyte
mitochondria (56).

Oxaloacetate concentrations depend upon

equilibrium with malate, which is determined by the
mitochondrial NAD^/NADH ratio; and conversion of

oxaloacetate to phosphoenolpyruvate (PEP) within the cytosol

by PEP carboxykinase (PEPQK)

(3,56).

Baird (2) found

8

significant differences between oxaloacetate concentrations
in livers of normal lactating cows and livers of ketotic
cows.

Excess NADH from beta-oxidation converts oxaloacetate

to malate, shunting malate out of the mitochondria and into

the cytosol for gluconeogenesis (3).

PEPCK activity is

increased in ketotic sheep, resulting in increased
conversion of oxaloacetate to PEP (3).

These two factors

enhance gluconeogenesis with concomitant depletion of the
mitochondrial oxaloacetate supply, resulting in reduced

entrance of acetyl-CoA into the TCA cycle and subsequent
flow of acetyl-CoA through the ketogenic pathway.
The elevated glucose requirement of pregnancy and

lactation increases the conversion of propionate, lactate,

and amino acids to glucose by the liver and kidney (3).
Since these substrates may be used for oxaloacetate

production, this contributes to the oxaloacetate deficiency,
and enhances ketogenesis.

Under the influence of the above factors, acetyl-CoA is
directed into the ketogenic pathway and groups of two
acetyl-CoA molecules condense to form acetoacetyl-CoA.

Acetoacetyl-CoA is then joined with acetyl-CoA by HMG-CoA
synthase to fonn HMG-CoA (Figure 3).

Acetoacetyl-CoA is a

negative feedback inhibitor of HMG-CoA synthase.

HMG-CoA is

split by HMG-CoA lyase to form acetoacetate and a different
acetyl-CoA from the original molecule.

Acetoacetate can be

spontaneously decarboxylated to produce acetone, or it can

o

o

II

II

CHj-C-CH^-Ca/S-CoA

CH3- c-v S-COA

HjO

AC£TOAC£TyL' CoA

ACETYL - CoA

J
I MMG • Co* 8v>sJTwasE

^CoA .SH
OH

O

CH3- C-CH.-C~S-CoA

*CH^—*COO-

i-HYDROXY' 3-A4ETNYL'

6LUTARYL- CoA (HMG - CoAJ
HMG-COA LVASE

f
o

CH - C
® *1

O
II

*

CH. — C~ S-CoA

CH^— COO"

ACET0ACE7ATE

ACETYL - CoA

Figure 3: Formation of acetoacetate through intermediate
production of HMG-CoA (Harper's, 1985).

10

be converted to beta-hydroxybutyrate by the addition of two

hydrogens (Figure 4).

This reaction relies upon beta-

hydroxybutyrate dehydrogenase, located in the cytosol of
sheep liver and kidney cortex (27), which is influenced by
the cytosolic NADH/NAD'" ratio.

During periods of increased

fatty acid oxidation, NADH production in the mitochondria

results in a lowered cytosolic NADH/NAD^ ratio, and very
little acetoacetate is converted to beta-hydroxybutyrate by
beta-hydroxybutyrate dehydrogenase (56).

Beta-

hydroxybutyrate dehydrogenase is not present in sheep liver
mitochondria, prohibiting acetoacetate conversion to betahydroxybutyrate in sheep liver mitochondria even under
reducing conditions (27).

Beta-hydroxybutyrate

dehydrogenase activity in cow liver is 1/30*^^ that in rat
liver (2).

HMG-CoA synthase is considered the rate-limiting enzyme
of the ketogenic pathway.

Although the other ketogenic

enzymes have been found in the heart, kidney and intestine,
. HMG-CoA synthase has been isolated only in the liver and in
very small quantities in

rumen epithelium (28).

The

hindlimb of fasted and diabetic dogs appears to be a

negligible source, and HMG-CoA synthase has not been found
in the extrahepatic tissues of the dog (1).

Its near

restriction to hepatic tissue accounts for the liver being

the primary site of ketogenesis in non-ruminants and fasted
ruminants (36).

11

CH3 —C—CH3
CO,
Acetone

CH3"C—CHj—COO
Acetoacetate
D(-I-3-HYDROXY8UTYRATE
DEHYDROGENASE

NADH + H""
NAD*"

OH

I

CH3-CH-CHJ-COO"
D(-)-3-hydroxylxjtyrate

Figure 4: Interrelationships of the ketone bodies
(Harper's, 1985).

12

Although alimentary ketogenesis provides approximately
7% of the fed ruminant's energy requirements through the
conversion of butyrate and some acetate to ketone bodies
(18), the liver is the main source of ketone bodies during
energy restriction, pregnancy, and lactation, relying on
NEFA released from adipose tissue (2,19).

Ketone Bodv Utilization

Ketone bodies produced in the liver are transported in
the blood to extrahepatic tissues.

Beta-hydroxybutyrate is

oxidized to acetoacetate, which is then activated by joining
with succinyl-CoA to form acetoacetyl-CoA and succinate, as

catalyzed by 3-oxoacid-CoA-transferase (38).

This enzyme is

abundant in most tissues except the liver, explaining why
the liver does not utilize the ketone bodies it produces.
Acetoacetyl-CoA is cleaved in the presence of a free CoA to
form two acetyl-CoA units.

The first and last steps of this

pathway are catalyzed by beta-hydroxybutyrate dehydrogenase
and acetoacetyl-CoA thiolase, which appear to be abundant in
all mammalian tissues (36).

Under normal, fed conditions the ruminant liver

experienced a net acetoacetate uptake, and a net beta-

hydroxybutyrate production (18).

After three days of

fasting, acetoacetate uptake reversed to production, and
beta-hydroxybutyrate production increased more than ten-fold
(20).

This condition was similar in one-day fasted.
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alloxan-diabetic sheep maintained at euglycemia with insulin
injections.

However, one-day fasted, untreated diabetic

animals displayed elevated acetoacetate production rates,
and beta-hydroxybutyrate production levels twenty-fold above
normal.

This accelerated ketogenesis following a lack of

insulin concurs with insulin inhibition of adipose lipolysis
at hormone-sensitive lipase (19).
When three day fasted animals were infused with a

ketone, acetoacetate production reversed to net uptake, and
beta-hydroxybutyrate production fell to 461 umol/min.

This

data represents the reversal of the fasting condition by the
ketone to the fed state (11).

The mitochondrial location of beta-hydroxybutyrate
dehydrogenase in rumen epithelium (28), and an increased

NADH/NAD" ratio in the fed ruminant, favors a high betahydroxybutyrate :acetoacetate ratio.

During progressive

fasting, alimentary ketogenesis ceases and peripheral free
fatty acid release increases to provide substrate for

hepatic ketogenesis.

Hypoinsulinemia accompanied by

hyperglucagonemia induces free fatty acid release from
adipose and subsequent hepatic oxidation.

Elevated hepatic

oxidation of free fatty acid contributes to an increased

mitochondrial NADH/NAD'' ratio, which, coupled with the
cytosolic location of beta-hydroxybutyrate dehydrogenase in
the hepatocyte, results in an increased acetoacetate:betahydroxybutyrate ratio (18,27).
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Acetoacetate may be responsible for the central nervous
system depression associated with ketosis (27).

The lack of

beta-hydroxybutyrate dehydrogenase in ruminant hepatocyte
mitochondria may explain -the high susceptibility of
ruminants to ketosis.

Under fasting conditions, the

ruminant liver can not reduce the acetoacetate:beta-

hydroxybutyrate ratio.

This contrasts with non-ruminants

such as the rat, where the enzyme is mitochondrial, and an
increased mitochondrial NADH/NAD^ ratio results in
accelerated conversion of acetoacetate to beta-

hydroxybutyrate, thereby having a detoxifying effect (27).
Acetoacetate utilization was concentration dependent up
to about 1 mM, at which point maximal utilization was

constant at 0.4g/hr/kg^''^ (4,5).

Acetoacetate contribution

to total exhaled COj increased from 2% under normal

conditions to 20% during pregnancy ketosis (5), implying
that utilization of acetoacetate during ketosis increased
ten-fold.

This suggests that overproduction rather than

underutilization was responsible for the toxic effects of
acetoacetate during ketosis.

Insulin and Glucaaon

During periods of carbohydrate deprivation, fatty acids
are oxidized in place of glucose, providing a glucose
sparing effect.
acid cycle.

This is known as the Randle glucose-fatty

Diabetics, however, experience abnormal fatty

15

acid metabolism, with elevated NEFA levels

(Yasuhiro,90)(47).

Insulin is required for the uptake of

glucose by most mammalian tissues, and its deficit results

in hyperglycemia with concomitant hyperlipidemia, as the
body attempts to utilize fatty acids during glucose
unavailability.
Ketone bodies are an important energy source for
diabetics, and concentrations elevated greater than ten-fold
normal levels are well documented (19). This suggests that
insulin has an important role in the regulation of
ketogenesis (34),

Because insulin did not stimulate beta-

hydroxybutyrate uptake in the perfused hindquarter of
diabetic or starved rats, it can be proposed that the

diabetic state displayed not only uncontrolled ketogenesis,
but a lack of ketone body uptake as well, resulting in
ketosis (22).
Keller et al. (25) stated that insulin exhibits two

methods of ketogenesis inhibition: the suppression of
hormone-sensitive lipase and a direct hepatic effect.
Somatostatin, an inhibitor of insulin and glucagon
secretion, produced a significant decrease in hepatic
glucose production.

The results were similar when glucagon

deficiency was achieved by somatostatin infusion accompanied
by intraportal insulin infusion.

This suggested that

glucagon was necessary for the stimulation of hepatic
glucose production.

Indeed, insulin deficiency accompanied
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by glucagon infusion resulted in a two-fold increase in

glucogenesis (25).

Insulin deficiency in the presence of basal glucagon
levels resulted in a 185% increase in hepatic ketogenesis
within one hour.

NEFA infusion induced a further increase.

Hypoglucagonemia with exogenous insulin did not present a
significant difference from control or bihormonal deficiency

(25).

Based on the elevated rates of hepatic ketogenesis

observed when insulin deficiency was coupled with basal

glucagon levels, it appeared that insulin had a modulating
effect on ketone body production in three-day fasted dogs.
The lack of an increase with selective glucagon deficiency
suggested that insulin displayed a stronger suppressive role
than glucagon did a stimulatory one.
Insulin infusion produced an increase in mitochondrial

GPAT activity in isolated rat liver, as reported by Zammit
(56), substantiating insulin's role in stimulating

triglyceride synthesis while inhibiting oxidative pathways
such as ketogenesis. Insulin lowered acetoacetate formation
in ketotic twin-pregnant ewes within one-half hour of
infusion (4).

Insulin decreases hepatic NEFA uptake, which

reverses ketosis in normal subjects.

However, endogenous

NEFA are readily available in subjects with fatty liver, and
only administration of agents blocking the carnitine
transport system can reverse ketosis in these subjects (34).

Insulin stimulates malonyl-CoA production by increasing
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acetyl-CoA carboxylase activity.

Malonyl-CoA inhibits fatty

acid transport into the mitochondria via CPT-I,

Therefore,

insulin has an indirect inhibition on hepatic ketogenesis.
The contribution of NEFA to ketogenesis increased in

diabetic humans displaying low insulin levels accompanied by
elevated NEFA and ketone body concentrations (6).

The

elevated NEFA levels were possibly due to an insulin
deficiency, which removed inhibition of hormone-sensitive

lipase at the adipocyte.

However, when NEFA was supplied by

triacylglyceride emulsion infusion, mild hyperinsulinemia
did not affect the production of ketone bodies from NEFA,

which suggested that insulin had a stronger regulatory role
at the adipocyte versus the hepatic site (6).

Beylot (6) proposed that insulin had no direct hepatic
effect toward inhibiting ketogenesis.

In human patients,

the proportion of NEFA used for ketogenesis was unaltered by
increasing insulin levels.

It should be noted that insulin

levels were physiological, and insulin may have had an
effect at pharmacological levels (6).

Insulin secretion in vivo may be a factor of nutrient
oxidation rates, including fatty acid oxidation rates.
Short- term NEFA infusion in dogs resulted in insulin
release, and stimulated insulin release in isolated

pancreatic islets and in perfused pancreas (54).

Yasuhiro

and Grill (54) reported that fatty acid oxidation in the
pancreatic islets inhibited insulin secretion.

Intravenous
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infusion of a 10% lipid emulsion in isolated perfused rat
pancreas produced a marked increase in insulin secretion

after 3 hours of administration, with the effect lessening
over time until insulin secretion was inhibited after 48

hours.

Inhibition occurred with normal and elevated glucose

levels (54).

If increased fatty acid oxidation stimulated

insulin release, insulin had a negative feedback on

peripheral lipolysis and acyl-CoA transport into the
mitochondrial matrix.

Glucagon infusion caused a decrease in hepatic removal
of ketone bodies in both normal and diabetic sheep (8).
Glucagon was proposed to have a stimulatory effect on
hepatic ketogenesis; possibly through the CPT-I mechanism

(26).

Glucagon diminishes the production of malonyl-CoA by

inhibiting acetyl-CoA carboxylase activity.

A decrease in

glucagon removes the inhibition on acetyl-CoA carboxylase,
allowing malonyl-CoA levels to rise in the presence of

insulin.

This interferes with the CPT-I system, and limits

ketogenic capacity.

Glucagon also stimulates hormone-

sensitive lipase via cAMP-PK, elevating circulating NEFA
concentrations, which makes more substrate available for

ketone production.
Glucagon release was studied in an experiment involving
infusion of a ketone following a fatty acid emulsion.

The

fat emulsion produced slight but not significant increases
in glucagon release, which were not altered by subsequent
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infusion of the ketone.

Glucagon did not appear to be a

regulatory mechanism in the inhibition of hepatic

ketogenesis brought on by beta-hydroxybutyrate (45).
Glucagon infusion induced an increase in hepatic
acetoacetate production but no change in beta-

hydroxybutyrate production in two-day fasted dogs.

Keller

and Shulman (26) proposed that glucagon stimulated
mitochondrial respiration; thereby lowering the betahydroxybutyrate ;acetoacetate ratio.

This suggested that the

hyperglucagonemia and insulin deficiency of diabetes
enhanced fatty acid oxidation and ketogenesis.

Basal

glucagon levels may not affect hepatic ketogenesis unless
insulin deficiency is present (25).

Given these conditions,

the stimulation of ketogenesis can be related to mechanisms
observed in acute diabetes.

Glucagon injection in rats

resulted in hepatic metabolism resembling that observed in
starved animals (55).

Glucagon acted at the hepatic level of regulation to
increase the proportion of NEFA converted to ketone bodies
in human subjects (6).
glucagon's effect.

However, insulin was able to reverse

A deficiency of insulin accompanied by

hyperglucagonemia may contribute to ketosis through
unchecked lipolysis and ketogenesis (8).
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Malonvl-CoA

Malonyl-CoA is a strong reversible inhibitor of CPT-I

(13,15), the mechanism responsible for initiating the
transport of free fatty acids across the inner mitochondrial

membrane so that oxidation may occur.

Both malonyl-CoA

concentrations and acetyl-CoA carboxylase activity are
decreased during ketosis (56), which removes direct

inhibition of CPT-I.

However, Cook et al. (10) suggested

that reduced sensitivity of CPT-I to malonyl-CoA inhibition,
rather than malonyl-CoA concentrations, may be a more

important regulator in starved rats.

Malonyl-CoA

concentrations were inversely related to ketogenic rates in
fed rats, but not in starved rats.

Starved rats required

much higher levels of malonyl-CoA in order to produce
inhibition of ketogenesis (10).

Cook (10) proposed that

this was due to increased rates of malonyl-CoA deacylates
during starvation, but cultures showed equal rates of
malonyl-CoA loss in fed and starved states.

It appears that

the liver is less sensitive to malonyl-CoA inhibition in the
starved state.

Zammit (56) proposed that mitochondrial CPT-

I may respond to malonyl-CoA and "remember" hepatic malonylCoA concentrations either by covalent modification (ie.

phosphorylation of the CPT-I) or by binding of an effector
molecule to the CPT-I.

Malonyl-CoA inhibition of CPT-I is readily reversible,
and can be overcome by high concentrations of palmitoyl-CoA.
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Muscle mitochondria are more sensitive to malonyl-CoA
inhibition than are liver mitochondria (13).

Malonyl-CoA concentrations varied with diet, exhibiting
an increase during carbohydrate feeding when liver
metabolism was directed toward fatty acid synthesis (36).

As hepatic malonyl-CoA concentrations rise, fatty acid
oxidation is inhibited (21).

Insulin release is stimulated,

promoting the breakdown of carbohydrate to acetyl-CoA and
subsequent conversion of acetyl-CoA to malonyl-CoA (35).
Acetyl-CoA carboxylase, the enzyme responsible for this

step, is stimulated by insulin and inhibited by glucagon
(21).

High levels of malonyl-CoA inhibit CPT-I, in essence

shutting down fatty acid oxidatioh (36).

In contrast,

starvation is characterized by elevated glucagon release,
which lowers malonyl-CoA concentrations and suppresses fatty
acid synthesis.

Increased flux of acyl groups into the

hepatic mitochondria stimulates fatty acid oxidation and
ketogenesis (36).

McGarry and Foster (35) treated male rats with glucagon
and 5-(tetradecyloxy)-2-furoic acid (RMI 14,514); both

inhibitors of hepatic malonyl-CoA synthesis; and reported
that malonyl-CoA suppression accompanied by elevated
carnitine concentrations in the liver contributed to

increased ketogenesis in animals fed glucose, lactate and
pyruvate in order to maximize fatty acid synthesis.
Enhancement of fatty acid oxidation by glucagon and RMI
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14,514 was not as prevalent when rats were fed high

concentrations of oleic acid.

It is possible that oleate

had an inhibitory effect on acetyl-CoA carboxylase, thereby
lowering malonyl-CoA production.

Therefore, the long chain

fatty acid relieved malonyl-CoA inhibition on fatty acid
oxidation.

Methvl Palmoxirate

Methyl palmoxirate is a fatty acid analog of palmitate
which irreversibly blocks CPT-I (32), inhibiting the
oxidation of long chain fatty acids, but not short chain

fatty acids or palraitoyl-carnitine (48).

Because fatty acid

oxidation results in decreased hepatic glucose utilization

and increased gluconeogenesis in species with cytosolic
PEPCK, methyl palmoxirate has an insulin-independent effect

of lowering glucose concentrations by stimulating glucose
utilization while decreasing glucose production.

This

results in lowered blood glucose and ketone concentrations

(48).

The liver appears to be more sensitive to methyl

palmoxirate than is muscle (48).

A human diabetic patient in severe hyperglycemia and
insulin resistance responded to oral methyl palmoxirate with
reduced fasting plasma glucose concentrations from 463 to

306 mg/dl.

The respiratory quotient increased from .71 to

.84, implying that carbohydrate oxidation increased during
treatment.

Glucose production was lowered, and plasma NEFA
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concentrations fell (32).

Oral methyl palmoxirate reduced plasma ketone
concentrations 83 to 93% in fasted rats 4 to 6 hours after

administration.

Ketones were significantly lowered with

oral doses ten-fold less than those required to

significantly reduce blood glucose, suggesting that methyl
palmoxirate is beneficial in the treatment of ketosis (48).

Carnitine

Carnitine is essential to fatty acid translocation into

the mitochondria (34).

Cardiac and skeletal muscle rely

heavily on fatty acids as an energy source, and therefore

require carnitine

(40).

Palmitic acid and other long chain

fatty acids require carnitine as a transporter across the
mitochondrial membrane (39).

Species lacking in CPT-I, such

as the blowfly, are incapable of oxidizing long chain fatty
acids (36).

Carnitine enhances fatty acid oxidation in vitro (16).

Isolated rat mitochondria with a carnitine deficiency
presented inhibited ketogenesis (10).

Addition of carnitine

to bovine liver slices and ovine hepatocytes increased NEFA

oxidation (15).

However, in hepatocytes from fasted sheep,

additional carnitine did not increase NEFA oxidation where

endogenous carnitine levels were already elevated (15).
Carnitine infused into the cranial mesenteric did not

increase hepatic ketogenesis in diabetic ewes (52).
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Carnitine concentrations are increased in the liver of

lactating dairy cows as opposed to non-lactating cows, and
fasted sheep versus fed sheep.

Carnitine may be obtained from the diet or synthesized
by the body (42).

milk (16).

It is excreted in the blood, urine and

During periods of stress or starvation,

proteolysis results in an increase in circulating amino
acids (3). Trimethyllysine is released from skeletal muscle

and taken up by the kidney, where it is converted to gammabutyrobetaine (15) (Figure 5).

Gamma-butyrobetaine is then

rapidly converted to carnitine in the liver and
transported to extrahepatic tissues (40).

It has been

proposed that acetyl-carnitine is transported via the blood
between the muscle and liver (14).

Stress increased carnitine synthesis by the liver (16).
Plasma free carnitine levels in human subjects decreased

during exercise, as free carnitine was incorporated into
acetyl-carnitine due to fat oxidation (14).

An increase in

protein turnover produces a subsequent increase in
trimethyllysine from protein, possibly stimulating carnitine
biosynthesis (40).

Perfused rat intestine and liver absorbed gammabutyrobetaine, but kidney did not (40).

Male rats

supplemented with 1% dietary gamma-butyrobetaine displayed
elevated L-carnitine levels, suggesting that gamma-

butyrobetaine was absorbed by the intestine, taken up by the
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Figure 5: Synthesis of carnitine (Frenkel, 1980).
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liver, and converted to L-carnitine.

When hepatocytes of fed rats were exposed to glucagon
and RMI 14,514, fatty acid oxidation and ketogenesis were
increased.

Subsequent addition of carnitine caused

ketogenesis to increase to rates observed in fasted animals
(35).

Carnitine concentrations as low as 10'^ M increased

long chain fatty acid oxidation in cardiac muscle (9).

This

data suggested that carnitine accelerated ketogenesis
through enhancement of the OPT-I transport mechanism.
Although carnitine acyl-transferases have been identified in

most mammalian tissues (36), CPT-I is specific to liver,
heart, kidney and skeletal muscle mitochondria (21).

Beta-hvdroxvbutvrate Infusion

Beta-hydroxybutyrate infusion decreased NEFA

concentrations in fasted and diabetic goats and sheep (16),
and increased insulin levels in normal sheep (19).

Elevated

insulin may inhibit adipose lipolysis, thereby lowering the
level of ketone bodies produced from NEFA (16).
In diabetic, insulin-treated sheep, ketone infusion had
a significant effect in returning accelerated ketogenesis to
rates observed in the fed state.

Even in a diabetic,

untreated ewe, ketone infusion significantly reduced betahydroxybutyrate production and reversed acetoacetate
production to net uptake (11).

Beta-hydroxybutyrate

infusion may reduce hepatic ketogenesis by inhibiting CPT-I.
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Three mechanisms are possible: a decrease in pancreatic
glucagon production, the stimulation of acetyl-CoA

carboxylase, and the direct inhibition of CPT-I by binding
(11).

Infusion of beta-hydroxybutyrate resulted in a
significant decrease in arterial plasma NEFA concentrations
in alloxanized sheep and dogs (30).

Heitmann and Fernandez

(19) reported lowered NEFA levels and decreased hepatic
uptake of NEFA following beta-hydroxybutyrate infusion in
normal, diabetic insulin-treated, and diabetic untreated

sheep.

Ketone infusion lowered hepatic extraction ratios in

normal and diabetic insulin-treated sheep, but not in
diabetic untreated sheep (19), which suggested that insulin

had an inhibitory effect on NEFA uptake by the liver.
Hepatic NEFA uptake increased 70% in diabetic untreated

sheep due to elevated free fatty acid levels, resulting in
constant hepatic extraction ratios (19).

Madison (30)

reported arterial NEFA concentration decreases of over 50%

following femoral vein ketone infusion, which suggested that
due to the similarity of the ketone infusion and insulin
infusion, the ketone may have produced a decrease in free
fatty acid by stimulating insulin secretion.
Beta-hydroxybutyrate infusion in partially diabetic

alloxanized dogs resulted in lowered arterial glucose and
NEFA concentrations.

A 196% rise in pancreatic-venous

insulin concentration was measured after 80 minutes of beta-
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hydroxybutyrate or acetoacetate infusion at 2.46 mmol/min
via the femoral vein (30),

Pancreatic-arterial infusion of ketone bodies at 0,125

mmol/min resulted in rapid release of insulin from the
pancreas.

Pancreatic-venous insulin levels rose 142% within

15 minutes and 800% by 80 minutes (30).

The immediate rise

in insulin concentrations following ketone infusion may have
been responsible for the hypoglycemia observed with the

hyperketonemia (30).

The decrease in blood glucose levels

in partially diabetic alloxanized dogs with elevated blood
glucose levels due to induced hyperketonemia, coupled with
no change in depancreatized dogs with near normal blood

glucose levels, led Madison et al. (30) to propose that the
release of insulin due to hyperketonemia is not similar to
glucose action.

Lipid Infusion

Lipid and heparin infusion resulted in an increase in

both arterial NEFA concentrations and hepatic free fatty
acid uptake, which was not affected by the presence or
absence of both pancreatic hormones.

This increase in

substrate availability induced a 149% increase in hepatic
ketogenesis, mostly attributable to increased betahydroxybutyrate production (25).

Lipid infusion also

stimulated lipoprotein lipase activity (39).
Infusion of fatty acid emulsion and heparin caused no
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significant change in plasma glucagon or insulin levels, but
resulted in a four to five-fold increase in glycerol
concentration due to lipoprotein lipase stimulation and
precursor supply.

Keller et al. (25) used glycerol

concentrations to monitor lipolysis, and reported no
significant change in arterial glycerol concentration with
hormone fluxes.

Glycerol uptake by the liver followed first

order kinetics despite hormone level alterations.

Oleic acid infusion in fed, diabetic untreated sheep
caused a significant increase in ketogenesis, whereas

octonoate infusion did not (50).

This suggests that CPT-I

is involved in the regulation of ketogenesis, since the long
chain fatty acid

is transported by CPT-I, but the medium

chain fatty acid is not (33).

In addition, beta-hydroxybutyrate infusion on top of
the fat emulsion reduced ketogenesis only with the long
chain fatty acid, suggesting that the C 18 was regulated at
CPT-I (50).

The purpose of this study was to establish if

gamma-butyrobetaine would be taken up by the liver and
converted to carnitine, and if the exogenous carnitine would

reverse the inhibition of hepatic ketogenesis brought on by
beta-hydroxybutyrate infusion in alloxan-diabetic ewes.
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CHAPTER III

MATERIALS AND METHODS

Animals

A possible insulin-independent regulatory mechanism of
hepatic ketogenesis was studied in eight experiments
conducted on five non-pregnant, non-lactating, alloxan-

diabetic crossbred ewes weighing 46 to 103 kg.

Animals were

housed individually in 1.8 x 3.0 m indoor pens under natural
lighting with ambient temperature maintained between 17 and

25 °C.

Commercially prepared alfalfa pellets were fed

according to the National Research Council

recommendation

in two daily aliquots of 450 g at 0800 and 1700 h.

Water

and trace mineralized salt were provided ad libitum.

Animals were accustomed to laboratory personnel prior to any
experimentation and only mild restraint was required for
sample collection.

Surgerv

Catheters were surgically positioned in hepatic, portal
(23) and femoral veins, a femoral artery (57), and two

mesenteric veins of each animal, so that the tips resided in
the hepatic vein, portal vein, caudal vena cava, caudal
aorta, and the common mesenteric vein (see Appendix 1).
Blood samples from the caudal aorta and caudal vena cava

were used in arterial and venous determinations of glucose.
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NEFA, acetoacetate and beta-hydroxybutyrate.

Hepatic and

portal vein blood samples were used to measure liver and

portal-drained visceral fluxes of glucose, NEFA,
acetoacetate, and beta-hydroxybutyrate.

The common

mesenteric vein served for infusion of para-aminohippuric
acid (PAH, Eastman-Kodak Co., Rochester, N.Y.) for whole
blood flow rate determinations.

Diabetes

Animals were allowed at least ten days to recover from

surgery, at which time ewes were made diabetic with a single
intravenous dose of alloxan (Sigma Chemical Co.) at 50 mg/kg
body weight at 1700 h.

Alloxan specifically destroys the

beta cells of the pancreas, inducing diabetes (43).
allowed the study of insulin-independent effects.

This

Animals

were closely monitored over the subsequent 24 hour period to
ensure a diabetic state, confirmed by arterial glucose
concentrations.

Daily insulin injections of Iletin-100 were

administered subcutaneously at 1300 h to reestablish and
maintain euglycemia (2.5 to 3.5 mM).

Insulin was withheld 3

days prior to each experiment, inducing a ketotic state for
the study of insulin-independent effects.

Feed intake

was noticeably decreased by the third day of insulin
withdrawal.
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Experiments

On the experimental day, infusion consisted of three
superimposed periods, with all infusates into the common

mesenteric vein (see Appendix 2).

Each period was two hours

in length, with the initial hour for equilibration of each
additional infusate and one hour for sample collection.

The

equivalence of a 30 minute infusion for each new infusate
was pulsed into the infusion site at the commencement of

each period.

The control period began at 0700 h with PAH

infusion (1.5% Eastman-Kodak Co.) into the first of the two

mesenteric veins at 0.764 ml/min (Model 940, Harvard

Apparatus).

During the second period, PAH was infused as in

the first period, while dl-beta-hydroxybutyrate was infused
into the same mesenteric vein at 1.18 mM/min (1.5445 M

solution, Sigma Chemical Co.).

Finally, the last period

consisted of PAH and dl-beta-hydroxybutyrate infused into
the first mesenteric vein, while gamma-butyrobetaine (1.5445
M, Sigma Chemical Co.) was introduced into the second

mesenteric vein.

Gamma-butyrobetaine was infused at a rate

equimolar to the BOHB infusion.
Following the 1 hour equilibration period, 12 ml blood
samples were drawn simultaneously from each of the four
remaining catheter sites at 30 minute intervals.

This

procedure was performed as each new infusate was

administered.

Samples were drawn into sterile syringes

containing 0.4 ml 6% NaEDTA, gently mixed, and immediately
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chilled on ice.

Throughout the experiment catheter patency

was maintained with 6% NaEDTA solution.

NaEDTA was used as

an anti-coagulant instead of heparin, because heparin

activates lipoprotein lipase and results in false high NEFA
values.

All analyses were completed on the day of the

experiment, except for insulin.

Plasma was separated and

frozen for future analysis of insulin.

Analvses

Whole blood was then analyzed for acetoacetate and
beta-hydroxybutyrate on all samples, and PAH on all but
femoral venous samples.

samples.

Plasma was analyzed for NEFA on all

Packed cell volume, blood glucose and plasma

insulin values were determined only on femoral arterial
samples.

If arterial insulin concentrations had been

significant, portal insulin samples would have been analyzed
to determine portal minus arterial values describing
pancreatic insulin release.

Plasma percent was determined

by subtraction of the hematocrit value from 1.

Analysis for ketone bodies, i.e. beta-hydroxybutyrate
and acetoacetate, was performed on 2 ml whole blood in cold

1 M perchloric aCid (53).

Glucose was determined by

spectrophotometer using a commercial kit (Sigma Chemical
Co.) and 200 ul whole blood.

analyzed for PAH (24).

One ml of whole blood was

A Wako NEFA-C kit (Wako Chemical

Co.) was used for the enzymatic assay of non-esterified
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fatty acids.

Arterial insulin concentrations were

determined from 200 ul of serum stored frozen, and a human

insulin kit (DPC #TKIN1).

NaEDTA has a tendency to cause

false high insulin values with this kit.

An equivalent

volume of NaEDTA was added to a second standard curve to

account for NaEDTA presence in the samples.

The regression

equation for the second standard curve was: y = 1.6206 +
.6580 X, r = .9934.

Calculations

The rate of PAH infusion (optical density units/min)
was divided by the venoarterial PAH concentration difference

(optical density units/L) across each tissue to determine
the blood flow rates.

Blood flow rates for hepatic and

portal veins were measured directly and the difference
between these two values was the hepatic arterial flow.

Multiplying blood flow rates by plasma percent determined
the plasma flow rates.
The venoarterial concentration differences across the

tissue multiplied by the respective blood flow rate equaled
the net flux.

A net release is indicated by positive

values, whereas a net uptake is indicated by negative
values.

Hepatic extraction ratios were calculated as the

fraction of the metabolite taken up by the organ relative to

the total concentration
time.

presented to the organ per unit

Significant differences between treatments would
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indicate intraorgan effects independent of blood flow and
concentration.

Statistical Analysis

Data was analyzed by comparing subsequent means of

consecutive treatments without interference to any other
treatments.

Means were separated by an unpaired t-test

within and among sheep and significance was considered at
the levels of (p<.05) and (p<.01), to determine the

significance of the infusates, dl-beta-hydroxybutyrate and
gamma-butyrobetaine, on energy metabolite concentrations and
fluxes.
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CHAPTER IV
RESULTS

Whole Blood Flow

Whole blood flow rates for the portal and hepatic veins
as well as the portal to hepatic vein blood flow ratio are

shown in Table 1.

Sequential infusions had no significant

effect on portal blood flow rates, which ranged from 2.1 to
2.5 L/min.

Hepatic blood flow was decreased from 3.6 to 2.5

L/min (P<.01) as a result of beta-hydroxybutyrate infusion.
Gamma-butyrobetaine infusion had no effect.

The portal to

hepatic ratio was low at 73% in the control period (20),
probably due to decreased portal circulation in the fasted

state and increased hepatic artery contribution bringing
peripheral NEFA to the liver.

This ratio increased from 73%

to 83% (p<.01) after beta-hydroxybutyrate infusion,
explained by increased portal vein contribution as more

blood was drained from splanchnic tissues as opposed to
peripheral tissues.

This could be due to exogenous beta-

hydroxybutyrate from the mesenteric vein reversing the
control.

Gamma-butyrobetaine had no effect on the portal to

hepatic ratio

or blood flow rates.

Glucose and Plasma Percent

Arterial glucose was not significantly altered during
the sampling period, remaining at 10 mM (Table 2); basically
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a three fold elevation of normal levels in non-diabetic

sheep (20).

Sequential infusions of beta-hydroxybutyrate

and gamma-butyrobetaine had no effect on plasma glucose.
Plasma percent (Table 2) ranged between 74 and 76;
slightly high.

Blood withdrawal did not result in a

significant change in plasma percent, meaning that blood
sampling did not stress the animals.

Non-esterifled Fatty Acids

Infusion of beta-hydroxybutyrate resulted in a 50%
reduction in arterial NEFA concentrations from 2144 to 1067

/xmol (p<.01, Table 3). Hepatic net uptake, indicating
removal of NEFA from the blood, decreased from 658 to 240

/xmol/min (p<.01) upon beta-hydroxybutyrate infusion.

Total

splanchnic uptake of NEFA also decreased 71% during betahydroxybutyrate infusion (p<.01).

release of NEFA was unaltered.

Portal-drained-visceral

Calculated hepatic

extraction ratios ranged from 9% to 6%, with no significant
change throughout the study.

Sequential infusion of gamma-

butyrobetaine had no effect on NEFA concentrations or net

fluxes.

Beta-hydroxybutyrate and gamma-butyrobetaine had no

significant effect (p>.05) on NEFA femoral venoarterial
differences.
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Acetoacetate

Arterial acetoacetate concentrations were 1167 /xmol

during the control period and increased to 1503 /xmol (p<.05.
Table 4) following beta-hydroxybutyrate infusion.

Portal

drained visceral net release of acetoacetate was 98 /xmol/min
during the control period, indicative of alimentary
ketogenesis.

Portal drained visceral release was unaltered

by infusion.

Infusion of beta-hydroxybutyrate decreased

hepatic net release of acetoacetate from 508 to 102 ^mol/min
(p<.01).

Because of the significant decrease in hepatic

release of acetoacetate following beta-hydroxybutyrate
infusion, total splanchnic release of acetoacetate also

decreased from 605 to 70 /xmol/min (p<.01).

Femoral

venoarterial differences always showed a net uptake of
acetoacetate by the hindquarter with no significant change
during any infusion period.

across the rump.

Blood flow was not measured

However, because portal vein contribution

to blood flow increased during ketone infusion, peripheral
blood flow rates could not have increased concomitant to a

splanchnic increase, assuming a constant cardiac output.
Therefore, it was assumed that hindquarter blood flow was
unaltered.

Subsequent gamma-butyrobetaine infusion had no

effect on any acetoacetate measurements.

180

pooled standard deviation of
pooled standard deviation of
* Significantly different from
** Significantly different from
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Beta-hvdroxvbutvrate

Arterial beta-hydroxybutyrate concentrations were 7582

/iitiol during the control period and increased to 12,349 /xmol
{p<.01, Table 5) due to beta-hydroxybutyrate infusion.

Portal drained visceral net release of beta-hydroxybutyrate
indicated alimentary ketogenesis of beta-hydroxybutyrate and
was not affected by any infusion.

Conversely, hepatic net

release of beta-hydroxybutyrate was decreased by more than

50% from 1586 t'o 700 /xmol/min with beta-hydroxybutyrate
infusion (p<.01).

Total splanchnic net beta-hydroxybutyrate

flux was not affected by any infusion period.

Femoral

venoarterial differences always showed a net uptake of beta-

hydroxybutyrate by the hindquarter.

Beta-hydroxybutyrate

venoarterial difference increased from 31 to. 439 /xmol
(p<.01) following ketone infusion.

Subsequent infusion of

gamma-butyrobetaine had no effect on net hepatic betahydroxybutyrate production.

Insulin

Arterial insulin concentrations are shown in Table 6.

Concentrations were small but different from zero, ranging
from 0.46 to 3.80 ^lU/ml.

This was similar to Fernandez

(19) and may represent cross reaction of the technique.

The

mean of all concentrations throughout the control period was

1.63 ± .48 /ilU/ml, and did not change significantly during
either infusion, so that all insulin means were combined.
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TABLE 5
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TABLE 6

EFFECTS OF SEQUENTIAL INFUSION OF BETA-HYDROXYBUTYRATE AND
GAMMA-BUTYROBETAINE ON MEANS OF ARTERIAL CONCENTRATIONS OF

INSULIN IN UNTREATED, ALLOXAN DIABETIC EWES^

TREATMENT

INSULIN

(MlU/ml)
Control

1.63

±.48
BOHB

1.04

pSTD^
GBB

.68
1.26

pSTD^
1

+.46

±.36
.60

means + standard error of means

::. pooled standard deviation of control and BOHB
3
pooled standard deviation of BOHB and GBB

Significantly different from the preceding infusion
period, p < .05.

Significantly different from the preceding infusion
period, p < .01.

46

resulting in a concentration of 1.25 ± .17 /lilU/ml.

Since

all other metabolites indicated successful alloxan diabetes,
portal insulin was not measured.
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CHAPTER V
DISCUSSION

This study was designed to evaluate the role of gammabutyrobetaine in restoring hepatic ketogenesis following
beta-hydroxybutyrate inhibition in insulin withdrawn
alloxan-diabetic ewes.

Arterial concentrations and net

portal drained visceral and hepatic fluxes and femoral
venoarterial differences of NEFA, acetoacetate and beta-

hydroxybutyrate were measured in untreated, alloxan-diabetic

ewes, as well as arterial concentrations of glucose and
insulin.

Infusion of beta-hydroxybutyrate into insulin-

withdrawn, diabetic ewes resulted in inhibition of hepatic
beta-hydroxybutyrate production (p<.01) and reversal of
acetoacetate production to hepatic uptake {p<.01)(11),

This

suggested that neither a functioning pancreas nor exogenous

insulin were required for the autoregulation of ketogenesis.
Infusion of oleic acid increased hepatic release of both

acetoacetate and beta-hydroxybutyrate (p<.05), whereas
octanoate infusion altered neither ketone production level.
Infusion of beta-hydroxybutyrate following the oleic acid

infusion decreased hepatic production (p<.05), suggesting
that CPT-I is a possible regulatory mechanism (45).
Wells (50) proposed that carnitine, because it

contributes to the CPT-I transport mechanism, may reverse
the inhibition of ketogenesis brought' on by beta-
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hydroxybutyrate infusion.

Carnitine did not restore hepatic

ketogenesis when infused at a rate equimolar to betahydroxybutyrate infusion; however, assays revealed that
infused carnitine was not removed by the liver.
This study proposed that gamma-butyrobetaine is taken

up by the liver upon infusion, and converted to carnitine;
thereby stimulating the CPT-I transport mechanism and

reversing any inhibition of hepatic ketogenesis brought on
by beta-hydroxybutyrate infusion.

Alloxan Diabetes

Mean arterial insulin concentrations ranged from 0.46

to 3.80 /xlU/ml over the eight experiments (Table 6), with
the average of the means being 1.25 ± .17 ^lU/ml, and
significantly different from zero, suggesting that either

some Ilentin-100 insulin remained or some cross reactivity
to the technique occurred.

The mean insulin concentration for the eighth

experiment was 3.80 ± .98 /xlU/ml, significantly higher than
the other experiments, indicating perhaps that this ewe

retained some

Ilentin-100 from her last injection prior to

the withdrawal period.

However, NEFA, acetoacetate, and

beta-hydroxybutyrate results were not different from the
other seven experiments.

Arterial glucose concentrations were 10 mM, well above
normal levels (20), indicating that the animals were indeed
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diabetic.

Arterial concentrations of acetoacetate, beta-

hydroxybutyrate and NEFA were elevated relative to normal

sheep (18,20), also suggesting that these animals were in an
insulin-deficient state.

A diabetic state ensures that acetyl-CoA carboxylase
will not be stimulated by endogenous insulin, which would

promote conversion of acetyl-CoA to malonyl-CoA, producing
an inhibitory effect on CPT-I (16), i.e., fat transport
across the inner mitochondrial membrane would

decrease.

An

insulin-withdrawn diabetic state removes all effects of

exogenous insulin, and forces the animal to rely heavily on
ketones as an energy source.

In a previous study, a decrease in glucagon release was

eliminated as a possible mechanism contributing to the betahydroxybutyrate inhibition of CPT-I (46).

If glucagon

levels decrease, lowered stimulation of hormone-sensitive

lipase results in lower concentrations of circulating NEFA,
making less NEFA available for ketogenesis.

Also, a

decrease in glucagon levels results in lowered inhibition of

acetyl-CoA carboxylase, resulting in increased malonyl-CoA
production, which inhibits CPT-I.

However, Sensenig (45)

observed a slight increase in portal drained visceral

release of glucagon, concomitant to beta-hydroxybutyrate
inhibition of hepatic ketogenesis, which suggested that
glucagon was not a contributing factor to regulation.
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Plasma Percent

Plasma percent was not altered during the experimental
period, suggesting that the volume of blood sampled
presented no stress to the ewes.

Portal and Hepatic Blood Flow

Portal vein blood flow showed no change following
addition of either infusates, whereas hepatic vein blood

flow decreased (p<.01) following beta-hydroxybutyrate

infusion.

This resulted in an increased (p<.01) portal to

hepatic ratio (Table 1).

An increased portal to hepatic

vein ratio implies that contribution from the hepatic artery
was lessened.

This could be explained by the exogenous

supply of nutrients infused into the mesenteric vein during
the second period, causing the portal vein contribution to

be increased relative to the hepatic artery since the portal
vein is carrying nutrients due to the ketone infusion.

Concomitant to the increase in nutrients from the portal

vein, the decrease in arterial NEFA concentration (p<.01)
may account for lowered hepatic vein blood flow, as less

nutrients come from the systemic circulation as opposed to
alimentary circulation.

Acetoacetate

Arterial acetoacetate concentrations were elevated

relative to normal sheep (18) and increased (p<.05)
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following beta-hydroxybutyrate infusion.
arterial levels

This increase in

represented conversion of beta-

hydroxybutyrate to acetoacetate within the animal.

Portal drained visceral release of acetoacetate during
the control period was indicative of alimentary ketogenesis

from rumen fermentation of organic matter and volatile fatty
acids, especially butyrate. However, variation was high
between sheep, since some of the ewes decreased feed intake

by the third day of insulin withdrawal.

Consequently, none

of the portal-drained visceral acetoacetate flux rates were
significantly different with infusate treatments.

Hepatic release of acetoacetate during the control
period was 508 /xmol/min (Table 4) and similar to values

reported in diabetic, untreated ewes (12,19,46,51,52).

Infusion of beta-hydroxybutyrate decreased hepatic
ketogenesis as observed by Dawes (12), Heitmann (19), and
Sensenig (46), but not Wells (51,52).

However, Wells

reported arterial insulin concentrations of 13.4 ^lU/ml,
suggesting that the ewes were not in complete insulinwithdrawal.

Total, splanchnic release of acetoacetate dropped from
605 to 70 /xmol/min (p<.01), depicting a net decrease in

acetoacetate release by the gut and liver following ketone

infusion, due to lowered production of acetoacetate by the
liver.

Femoral venoarterial differences for acetoacetate were
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not significantly different from zero, but did not differ

between infusion periods, suggesting that the rump did take
up acetoacetate.

Uptake by the hindquarter was not altered

by any infusion.

Infusion of gamma-butyrobetaine did not alter

acetoacetate concentrations or flux rates to a significant
level.

Beta-hvdroxvbutvrate

Arterial beta-hydroxybutyrate concentrations were

elevated relative to normal sheep (18) and increased (p<.01.
Table 5) following beta-hydroxybutyrate infusion.

increase represents the ketone being infused.

This

All other

values were corrected for ketone infusion.

Beta-hydroxybutyrate portal drained visceral fluxes

were positive, indicative of alimentary ketogenesis from

rumen fermentation of organic matter, and were unaltered by
infusions, suggesting that infusion did not decrease betahydroxybutyrate production by the gut.

Hepatic release of beta-hydroxybutyrate during the
control period was 1586 /xmol/min and similar to values

reported on diabetic untreated ewes (12,19,46,51,52).

Infusion of beta-hydroxybutyrate decreased hepatic
ketogenesis as observed by Dawes (12), and Heitmann (19),
but not Wells (51,52).

However, Wells has arterial insulin

concentrations of 13.4 /xlU/ml, suggesting that the ewes were
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not in complete insulin-withdrawal.

Total splanchnic release of beta-hydroxybutyrate was

not altered significantly, despite the reduction in hepatic
release, although there was a numerical decline.

Hindquarter uptake of beta-hydroxybutyrate was

negative.

It increased with infusion, suggesting that

exogenous beta-hydroxybutyrate provided a significant energy
source for the hindquarter.

Gamma-butyrobetaine infusion had no significant effects
on beta-hydroxybutyrate concentrations or flux rates.

Non-esterifled Fattv Acids

Arterial NEFA concentrations were significantly
decreased (p<.01. Table 3) by beta-hydroxybutyrate infusion.

It has been proposed that beta-hydroxybutyrate may have an
autoregulatory effect on hepatic ketogenesis by inactivating

hormone-sensitive lipase and thus lowering circulating NEFA
concentrations (15).

However, venoarterial differences

across the rump in this study showed no significant changes
in NEFA concentrations after beta-hydroxybutyrate infusion,
suggesting that beta-hydroxybutyrate had no effect on
peripheral lipolysis.

Dawes (11) demonstrated that beta-

hydroxybutyrate infusion decreased NEFA flux across the rump
in normal and diabetic insulin-treated ewes but not in

diabetic insulin-withdrawn ewes, suggesting that the
mechanism of beta-hydroxybutyrate inhibition at the
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3.dipocyte may work through insulin.

Blood flow ratss were

not measured across the hindquarter, because PAH was infused

into the common mesenteric vein and would have been cleared
by the kidney, but portal vein contribution to blood flow

increased during beta-hydroxybutyrate infusion (p<.01. Table
1), suggesting that with a constant cardiac output,
peripheral flow rates would not increase concomitant to a

splanchnic increase.

Assuming no increase in rump flow, no

change in venoarterial difference of NEFA represents no
change in peripheral lipolysis following beta-

hydroxybutyrate infusion.

Ketone infusion did not appear to

alter hormone-sensitive-lipase activity.
Wells (50) reported no decrease in net hepatic release

of beta-hydroxybutyrate following beta-hydroxybutyrate
infusion in insulin-withdrawn, alloxan-diabetic ewes.

Heitmann and Fernandez (19) reported no change in
ketogenesis due to beta-hydroxybutyrate infusion in

diabetic, untreated sheep.

In contrast, Dawes (11) reported

significant decreases in net hepatic release of beta-

hydroxybutyrate following beta-hydroxybutyrate infusion in
normal, insulin-treated, and insulin-withdrawn ewes.

Hepatic production of both acetoacetate and beta-

hydroxybutyrate decreased significantly- in this study
following beta-hydroxybutyrate infusion (p<.01).

This

concurs with a lowered hepatic uptake of NEFA following
beta-hydroxybutyrate infusion (p<.01).

Wells (50) also
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reported a decreased hepatic uptake of NEFA, but cited a
significantly decreased hepatic extraction ratio as well.

In contrast, the hepatic extraction ratio in this study was

slightly but not significantly lowered.

Katz and Bergman

(24) reported constant hepatic extraction ratios between 9

and 13-s in pregnant and fasting sheep.

A constant hepatic

extraction ratio concomitant with decreased circulating NEFA
levels agrees with decreased ketogenic production, since
hepatic extraction obeys first order kinetics (15,56).
Portal drained visceral release of NEFA was not

significantly altered by infusions. Total splanchnic uptake
decreased following beta-hydroxybutyrate infusion (p<.01),
which concurred with the decrease in hepatic uptake of NEFA
(p<.01) with a constant portal drained visceral release.
Gamma-butyrobetaine infusion had no effect on NEFA
concentrations or flux rates.

The average plasma NEFA of the ruminant is

approximately 17 carbons in length (49).

Using this figure,

each NEFA arriving at the liver is capable of producing 4.25
ketone bodies (24).

Table 3 shows hepatic uptake of NEFA in

the control period was 658 ^mol/min.

Multiplied by a factor

of 4.25, this represents a potential production of 2797
ketone bodies.

Hepatic production rates of beta-

hydroxybutyrate and acetoacetate for this period were 1586
and 508 /xmol/min, representing a total of 2094 four-carbon

units.

This suggests that 75% of the NEFA taken up by the
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liver in an insulin-withdrawn diabetic state is converted to

ketone bodies.

In the second period, hepatic uptake of NEFA

was 240 /zmol/min, and ketone production by the liver
totalled 802 /xmol/min, representing 79% of hepatic NEFA

uptake.

These percentages concurred with Katz and Bergman

(24).

It appears that although the infusion of beta-

hydroxybutyrate lowered both hepatic uptake of NEFA (p<.01)
and production of beta-hydroxybutyrate and acetoacetate

(p<.01), it did not alter the proportion of NEFA taken up by
the liver which was converted to ketone bodies.

Infusion of

gamma-butyrobetaine resulted in no change in hepatic NEFA
uptake, which was 217 /xmol/min, or a potential 922 ^mol/min
ketone bodies.

Although acetoacetate production did not

change significantly at 96 ^mol/min, beta-hydroxybutyrate
production measured 1260 /imol/min, bringing total ketone
production to 1356 /imol/min.

It is not possible that 1356

)Umol/min were produced from a potential NEFA contribution of
922 /xmol/min.

One explanation is that other sources

contributed to ketone production, such as butyrate and amino
acids, but this is unlikely considering that feed intake had

decreased one to two days prior to the experiments in some
ewes.

Hepatic uptake of butyrate in fed ewes was only 21

/imol/min, resulting in a potentially small contribution of

21 ^mol/min to ketone bodies, and this decreased by 71%
during energy restriction (29).

A more likely explanation
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is that the rate of beta-hydroxybutyrate production measured
in the third infusion period was numerically but not

significantly elevated due to tremendous variation among and
between sheep associated with determinations at high
concentrations.

Since values of NEFA contribution to ketone

production in the first two periods agree with Katz and
Bergman (24), and because gamma-butyrobetaine infusion

caused no significant changes, it is likely that NEFA

contribution to hepatic ketogenesis in the third period was
not significantly different from those values in the first
and second periods.

Since the rate of re-esterification of NEFA is passive
and totally dependent upon the rate of beta-oxidation, it
would appear that the rate of hepatic ketogenesis is
dependent upon NEFA uptake and the rate of beta-oxidation.

Because the percent NEFA converted to ketones did change,

beta-hydroxybutyrate does not appear to have a regulatory
effect associated with insulin or CPT-I.

Control of the

beta-hydroxybutyrate mechanism may be within NEFA uptake.
Gamma-butyrobetaine had no effects on beta-hydroxybutyrate
or acetoacetate concentrations or flux rates, suggesting
that either it was not taken up by the liver, was not

converted to carnitine, or was not a regulatory mechanism.
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APPENDIX A
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APPENDIX B

240
241
270
300
330

210,

0
60
90
120
121
180

TIME
(min)

GBB

SAMPLE 7A, 7H, 7P, 7V
SAMPLE 8A, 8H, 8P, 8V
SAMPLE 9A, 9H, 9P, 9V

INFUSED GBB 1.18 mmol/min

SAMPLE 4A, 4H, 4P, 4V
SAMPLE 5A, 5H, 4P, 5V
SAMPLE 6A, 6H, 6P, 6V

INFUSED BOMB 1.18 mmol/min

SAMPLE 1A, 1H, IP, IV
SAMPLE 2A, 2H, 2P, 2V
SAMPLE 3A, 3H, 3P, 3V

INFUSED 1.5% PAH @ 0.764 ml/min

COMMENT

APPENDIX B. Experimental protocol.

INFUSATESPAH
BOMB

PROTOCOL

O
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GLUCOSE ANALYSIS

Whole blood glucose determination utilizing the Sigma
Chemical Company Glucose Procedure No. 510 Kit is based upon

the following coupled enzymatic reactions:
glucose oxidase

Glucose + 2H2O + O2

> Gluconic acid + 2H2O2
peroxidase

H2O2 + o-Dianisidine

(colorless)

> oxidized o-Dianisidine

(brown -color)

Reacents (included with kit):

A)

PGO Enzymes (500 units glucose oxidase, 100
Purpurogalin units peroxidase and buffer salts),
(cat. # 510-6).

One capsule is diluted with dH20 to 100 ml and
stored in an amber bottle at 0 to 5 "C.

B)

o-Dianisidine Dihydrochloride, (cat. # 510-50).

Pre-weighed vial is diluted with dH20 to 20 ml and
stored at 0 to 5 °C.

1.6 ml of this solution is added to 100 ml of PGO
enzyme solution.

C)

Glucose Standard Solution (lOOmg/dl), (cat. # 635100)

Consists of a solution of beta-D-glucose, 100 mg/dl

in benzoic acid, 0.1%, and stored at 0 to 5 °C.
Other Reagents

A)

0.3 N Barium Hydroxide Solution, Sigma (cat. # 14-3)

B)

0.3 N Zinc Sulfate Solution, Sigma (cat. # 14-4)

Sample Collection and Preparation

Blood samples should be collected in a container with a

suitable anticoagulant.

Immediately after sample is
collected, pipette 0.2 ml blood into test tube containing

1.8 ml dH20, then mix. To each tube add 1.0 ml barium
hydroxide, vortex, then add 1.0 ml of zinc sulfate and
vortex again.
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Blank and standard are prepared in a similar manner except

0.2 ml dHjO and 0.2 ml of glucose standard are used,
respectively, in place of blood.

Tubes are then centrifuged at 3g for 15 min. at 0 to 5 oc.
Analysis

Prepare unknown, blank, and standard tubes in duplicate as
follows:

To each tube add 0.2 ml of supernatant from the respective
centrifuged unknown, blank and standard tubes followed by
2.0 ml of PGO/color solution and vortex.

Incubate all tubes at 37 °C for 30 min. in a waterbath or at
room temperature for 45 min.

Avoid direct exposure to sunlight or bright light.
Following incubation, remove all tubes from the waterbath.
Read at 450 nm.

Readings should be completed within 30 min.
Calculations

Blood Glucose (mg/dl) =

Absorbance of unknown
Absorbance of standard

x 100
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NON-ESTERIFIED FATTY ACID ANALYSIS
Principle

Plasma non-esterified fatty acid concentrations can be

determined using a WAKO NEFA C kit which is based upon the

following reactions:

R-COOH + ATP + CoA

> Acyl-CoA + AMP + PP^

acy1-CoA synthase

Acyl-CoA + O2

> 2,3-trans-enoyl-CoA + HjOj
acyl-CoA oxidase

2 H2O2 + MEHA + 4-AAP

> Purple Quinone Product

peroxidase
MEHA = 3-methyl-N-ethyl-N-(jS-hydroxyethyl)-aniline

4-AAP = 4-aminoantipyrine

Reagents (included with kit):

A) Color Reagent "A":
Acyl-CoA synthase
Ascorbate oxidase
CoA
ATP

4-aminoantipyrine

B) Diluent for Color Reagent "A":
0.05 M Phosphate Buffer, pH 6.9
Magnesium chloride
Surfactant
Stabilizers

C) Color Reagent "B":
Acyl-CoA oxidase
Peroxidase

D) Diluent for Color Reagent "B":
MEHA

Surfactant

E) NEFA standard Solution:

Oleic acid (1000 /xeq/L)
Surfactant
Stabilizers

+4H2O
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Procedure

1) Preparation of standards:

Dilute the standard provided (1000 iieq/l) with dHjO

to provide 125, 250, and 500 /ieq/liter standards.

Validation tests show that dHjO is an acceptable

dilutent.

2) Preparation of reagents:

Mix color reagent "A" by adding 10 ml of the specific

dilutent "A" to each vial.

Gently invert the vial

until contents are completely dissolved and then
combine with 13.3 ml dHjO. Store at 2°C to 10°C for

up to 5 days.

Mix color reagent "B" by adding 20 ml of the specific

diluent "B" to each vial.

Gently invert until

contents are dissolved and then combine with 33.3 ml

dHjO.

Store at 2°C to 10°C for up to 5 days.

Analvsis

1)

Assay each sample and standard in duplicate.

2)

Add 0.4 ml dHjO to each tube.

3)

Add 0.01 ml of serum, plasma or standard to each

tube, followed by 0.35 ml of the combined reagent "A"
plus dHjO mixture. Mix and refrigerate for up to 60 .
min if necessary.

4)

Incubate tubes in a waterbath at 37°C for exactly 20
min.

5)

Following incubation, add 0.8 ml of the combined
reagent "B" plus dHjO mixture to each tube, mix and

incubate a second time at 37°C for exactly 20 min.

6)

Remove tubes from waterbath, allow to equilibrate at
room temperature for 5 min, then record the OD at 550

nm using a blank prepared with reagents as zero.
Important

Do not mix reagents and supplies from test kits bearing
different lot numbers.

The assay is sensitive to heparin and plasma samples using
heparin as an anticoagulant are unsuitable.

Samples which are hemolyzed or overtly icteric may yield
inaccurate results.

Ascorbic acid interferes with assay so ascorbate oxidase
is automatically included in reagent "A" mixture in WAKO
kit.
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ACETOACETATE ANALYSIS

Principle

The acetoacetate analysis is a spectrophotometric
determination based upon a compound's (nicotinamide adenine

dinucleotide, NAD) unique property to absorb a specific
quantity of light of specific wavelength. Acetoacetate is

indirectly determined from the concentration of NAD
following the chemical reaction:

HOOC-CH2-CO-CH3 + NADH +
acetoacetate

> HOOC-CH2-CHOH-CH3 + NAD*
beta-hydroxybutyrate

Acetoacetate is reduced, in a 1:1 stoichiometry, using
reduced nicotinamide adenine dinucleotide (NADH) in the

presence of the enzyme beta-hydroxybutyrate dehydrogenase
resulting in the formation of beta-hydroxybutyrate and
oxidized nicotinamide dinucleotide (NAD*). The change in
absorption between the reduced and the oxidized forms of

nicotinamide adenine dinucleotide results in the calculation
of acetoacetate.
Treatment of Blood

1)
2)

3)

Mix equal volumes of whole blood and 1 M HCLO4

immediately after sampling.

Centrifuge at 3g for approximately 15 minutes.

Neutralize excess HCLO4 with KOH so that the final pH
is between 6.0 and 8.0.

4)

Centrifuge off the potassium perchlorate formed at
approximately 3g for 15 minutes and then pipette from
the supernatant.

5)

Samples must be analyzed the day of collection.

Reagents

1)

0.1 M Phosphate Buffer (pH 6.8)
1.36 g KH2PO4

>

100 ml dH20

1.74 g K2HPO4

>

100 ml dH20

Mix equal volumes of each solution.
the other to balance pH.

Check pH and add one or
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2)

NADH (approx. 1 mM) (Disodiutn Salt) (Grade II, 98%
Pure) (Boehringer Mannheim, cat, # 128023)
0.010 g NADH

>

6.0 ml dHjO

Make up on day of use.

3)

3-Hydroxybutyrate Dehydrogenase (5.0 mg/ml) (Grade II)
(Boehringer Mannheim, cat. # 127841)

4)

1.5 mM Acetoacetic Acid (ACAC) (Lithium Salt)

(90 to 95% Pure) (Sigma Chemical Co., cat. # A-8509)
0.01620 g CH3COCH2COOH ---> 100 ml dHzO
Standards

Dilute to the following concentrations for the working
standards:

0.15, 0.09, 0.075, 0.045, and 0.0225 mM.

Use two zero concentration standards as blanks.

The standards must be taken through the entire procedure as
small amounts of perchlorate will affect enzyme activity.
Pipette into conical centrifuge tubes:

1.0 ml standard and 1.0 ml of 1 M HCLO4.
Neutralize to pH 6.0 to 8.0. (Remember to record the volume
of buffer added to adjust pH !!!).
Centrifuge at 3g for 15 minutes.
Standard dilutions:

A)

0.15

->

2.0 ml of 1.5 mM ACAC plus 18.0 ml dHjO

B)

0.09

> 12.0 ml of A plus 8.0 ml dHjO

C)

0.075

>

D)

0.045

> 10.0 ml of B plus 10.0 ml dHjO

E)

0.025

> 10.0 ml of D plus 10.0 ml dHjO

4.0 ml of A plus 4.0 ml dHjO
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Analysis

Pipette into 12 X 75 mm culture tubes:
0.5 ml buffer

Sample - 0.25 ml plus 0.75 ml dHjO
Standard - 1.0 ml
0.05 ml NADH
Read

at 340 nm.

Add 0.005 ml 3-Hydroxybutyrate Dehydrogenase, vortex,

and incubate at room temperature for approximately 22
minutes.

Read Ej at 340 nm.
Important

NADH will "react" slowly at room temperature but at
about the same rate in all samples. The zero
concentration ACAC standards can be used as a control

for this.

Pipette NADH into all of the cuvettes at

known time intervals, i.e., 15 to 60 s.

Then read E^

in all cuvettes at same timed intervals. Incubate and

read Ej at same timed intervals.
Calculations

Calculate E^ minus Ej for all standards, samples and
blanks:

Change in E of standard minus change in E of blank.
Change in E of sample minus change in E of blank.
Plot a standard curve of change in E of standard versus
concentration.

Read the concentration of the samples from the curve.
Multiply by appropriate dilution factors.
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BETA-HYDROXYBUTYRATE ANALYSIS
Principle

The beta-hydroxybutyrate analysis is a spectrophotometric
determination based upon a compound's (nicotinamide adenine
dinucleotide, NAD) unique property to absorb a specific
quantity of light of specific wavelength, Betahydroxybutyrate is indirectly determined from the
concentration of NAD following the chemical reaction:
HOOC-CH2-CHOH-CH3 + NAD*

> COOH-CH2-CO-CH3 + NADH + H*

beta-hydroxybutyrate

acetoacetate

Beta-hydroxybutyrate is oxidized, in a 1:1 stoichiometry,
using oxidized nicotinamide adenine dinucleotide (NAD*) in
the presence of the enzyme beta-hydroxybutyrate
dehydrogenase resulting in the formation of acetoacetate and

reduced nicotinamide dinucleotide (NADH).

The change in

absorption between the reduced and the oxidized forms of

nicotinamide adenine dinucleotide results in the calculation

of beta-hydroxybutyrate.
Treatment of Blood

1)

Mix equal volumes of whole blood and 1 M HCLO4
immediately after sampling.

2)

3)

Centrifuge at 3g for approximately 15 minutes.

Neutralize excess HCLO4 with KOH so that the final pH
is between 6.0 and 8.0.

4)

Centrifuge off the potassium perchlorate formed at
approximately 3g for 15 minutes and then pipette from
the supernatant.

5)

Samples must be analyzed the day of collection.

Reagents

1)

0.1 M Tris-HCL Buffer (pH 8.5)

2.42 g Tris
pH

--->

>

50 ml dH20

8.5 with 1 M HCL

Final volume

>

200 ml
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2)

Hydrazine-Tris Buffer (Burnt Bacon Buffer)
2.5 ml Hydrazine Hydrate
0.05 g EDTA
12.5 ml 1 M HCL

Volume

> 50 ml with Tris-HCL Buffer

Check pH, should be 8.5
Make up on day of use.
3)

14 mM NAD'" (Free Acid) (Grade II, 98% Pure) (Boehringer
Mannheim, cat. # 127990)

0.06 g MAD^

> 3.0 ml dHjO

3)

3-Hydroxybutyrate Dehydrogenase (5.0 mg/ml) (Grade II)

4)

2.0 mM 3-Hydroxybutyric Acid (Sodium Salt) (98% Pure)
(Sigma Chemical Co., cat. # H-5501)

(Boehringer Mannheim, cat. # 127841)

0.0656 g CH3CHOHCH2COOH

> 250 ml dHjO

Standards

Dilute to the following concentrations for the working
standards:

2.0, 1.6, 1.2, 0.8, and 0.4 mM.

Use two zero concentration standards as blanks.

The standards must be taken through the entire procedure as
small amounts of perchlorate will affect enzyme activity.
Pipette into conical centrifuge tubes:
1.0 ml standard and 1.0 ml of 1 M HCLO4.

Neutralize to pH 6.0 to 8.0. (Remember to record the volume
of buffer added to adjust pH !!!).
Centrifuge at 3g for 15 minutes.
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Standard dilutions:

A)

2.0

>

20.0 ml of 2.0 mM BOHB plus 0.0 ml dHsO

B)

1.6

>

16.0 ml of 2.0 mM BOHB plus 4.0 ml dHjO

C)

1.2

>

12.0 ml of 2.0 mM BOHB plus 8.0 ml dH20

D)

0.8

>

8.0 ml of 2.0 mM BOHB plus 12.0 ml dH20

E)

0.4

>

4.0 ml of 2.0 mM BOHB plus 16.0 ml dH20

Analysis

Pipette into 12 X 75 mm culture tubes:
0.5 ml buffer

Sample - 0.10 ml plus 0.90 ml dHjO
Standard - 0.25 ml plus 0.75 ml dH20
0.05 ml NAD"

Read El at 340 nm.

Add 0.005 ml 3-Hydroxybutyrate Dehydrogenase, vortex, and
incubate at room temperature for approximately 45 minutes.
Read E2 at 340 nm.
Important

NAD" and hydrazine form a complex which absorbs at 340 nm.
Therefore, a slow constant increase in absorbance occurs.

This is similar to the acetoacetate assay but in reverse.
So pipette the NAD" and enzyme and take the absorbance
readings at timed intervals as described for the
acetoacetate assay.
Calculations

Same as for acetoacetate, except change in E is calculated
from E2 minus Ei.
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INSULIN ANALYSIS

Principle

^^®I-labeled insulin competes with insulin in the patient

sample for sites on insulin-specific antibody immobilized to
the wall of a polypropylene tube. After incubation,
isolation of the antibody-bound fraction is acheived by
decanting the supernatant. The tube is then counted in a

gamma counter, the counts being inversely related to the
amount of insulin present in the patient sample.

The

quantity of insulin in the sample is then determined by

comparing the counts to a standard curve.
Collection

Collect blood and separate serum from cells.

Avoid

hemolysis, since it has been shown to interfere with insulin
immunoassays involving standard separation methods. Samples
may be stored at 2 to 8°C for 7 days, or up to 3 months at
-20*'C. Avoid repeated thawing and freezing. Allow samples
to come to room temperature before assay; do not thaw frozen

samples by heating in a water bath.

Mix by gentle swirling

or inversion.Reagents

1)

Insulin

Add 100 ml dHjO and mix by gentle inversion.
2 to 8°C up to 30 days.

2)

Store at

Standards

Reconstitute calibrator "A" with 6.0 ml dHjO.

Reconstitute calibrators "B" through "G" with 3.0 ml

dHjO.
Procedure

1)

Label four uncoated 12 X 75 mm polypropylene tubes "T"
(total counts) and "NSB" (nonspecific binding).Label
fourteen coated tubes (provided in kit) "A" (maximum
binding) and "B" through "G" in duplicate.

2)

Pipette 200 fil of calibrator "A" into the "NSB" and "A"
tubes. Pipette 200 ^1 of each remaining calibrator,
control, and patient sample into the tubes prepared.
Pipette directly to the bottom.

3)

Add 1.0 ml of
Set

Insulin to ewery tube and vortex.

the "T" tubes aside.

Insulin addition should be
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completed in no more than forty minutes after step 2.
4)
5)

6)

Incubate for 18 to 24 hours at room temperature.
Decant all tubes except the "T" tubes.

Allow tubes to

drain for 2 to 3 minutes, then strike sharply on
absorbent paper to shake off residual droplets.
Count for 1 minute in a gamma counter.

Calculation

1)

Calculate for each tube the average "NSB"-corrected
counts per minute:
Net Counts = Average CPM - Average "NSB" CPM

2)

Determine the binding oe each tube as a percent of
maximum binding "MB", with the "NSB"-corrected counts
of the "A" tubes taken as 100%:

Percent Bound =

Net Counts

X

100

Net "MB" Counts

3)

Plot Percent Bound on the vertical axis against
Concentration on the horizontal axis for each of the

calibrators "B" through "G", and draw a straight line
through these six points. Insulin concentrations for
the unknowns may then be estimated from the line by
interpolation.
Important

All components must be at room temperature before use.
An automatic pipetter is not recommended for this
assay.

Crossreactivity with pro-insulin at mid-curve is
approximately 40%.

The procedure can detect as little as 1.2 /xlU/ml
insulin.

EDTA plasma yields falsely elevated insulin levels in
this assay. Therefore, if EDTA has been used as an
anti-coagulant, a second set of standards should be
used with an equivalent amount of EDTA added as present
in the samples.
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PARA-AMINOHIPPURIC ACID ANALYSIS

Reagents for Filtrate

1)
2)

Double Distilled H2O
20% Trichloroacetic Acid (TCA) (CCI3COOH)

(Sigma Chemical Co., cat. # T-6399)

Method for Filtrate

1)

Pipette

1.0

ml

of

blood

or

standard

into

15

ml

centrifuge tube containing 5.0 ml dHjO.

2)

Pipette 5.0 ml of blood or standard mixture into

3)

Let stand 60 min or overnight (can be left at this
stage if refrigerated.

4)

Filter through Whatman #4 filter paper into 16 x
150 mm glass culture tubes.

5)

Add boiling chip to each culture
marble on top of each tube.

tube

6)

Boil over low heat in water bath
fine bubbles appear in each tube.

for

min

after

7)

Cool at room temperature and remove marbles when

cool.

8)

Standards

15 ml centrifuge tube containing 5.0 ml 20%

along

from

with

1.5%

this

PAH

using

infusion

same

TCA.

and
30

solution

method

as

second

place

are

for

a

made

blood

filtrate.

Make

up

solution;

a

1:500

1:100

dilution

for

dog

for

from

sheep

0.25%

from

1.5%

infusion

infusion

solution

(considered 10:10).

Be sure to run this dilution through the filtrate procedure
(do not have to boil).
Blank mixed with half dHoO and half TCA (20%).
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Reagents for Analysis

1)

1.2 N Hydrochloric Acid (HCl)
(Fisher Scientific Co., cat. # A-144-S)

(1:10 dilution of 12.4 N HCl close enough)
2)

Sodium Nitrite (NaNOz)

(Sigma Chemical Co., cat. # S-2252)
ICQ mg NaNOj

3)

> 100 ml HjO

Ammonium Sulfamate (NH4OSO2NH2)

(Sigma Chemical Co., cat. # A-8670)
500 mg Ammonium Sulfamate

4)

> 100 ml H2O

Coupling Reagent N(-1-Naphthyl)Ethylenediamine
(Sigma Chemical Co., cat. # N-5889)
500 mg coupling reagent

> 100 ml H2O

All reagents should be refrigerated in brown bottles and can
be stored indefinitely.
Analysis

1)

Pipette 1.0 ml of filtrate, standard or blank into test

2)

Add 0.2 ml of 1.2 N HCl to all tubes and vortex.

tube (in duplicate).

The following steps should be done with no more
than 5 min between additions and tubes should be
vortexed after each addition.

Start time clock and add to all tubes:
0.1 ml sodium nitrite
0.1 ml ammonium sulfamate

0.1 ml coupling reagent

3)

Wait 10 min (minimum) for color development.

4)

Read absorbance on spectrophotometer at 540 nm.

5)

Calculations
standard.

are

made

as

a

percentage

of

100
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PAH Stock Solution

1)

Para-Aminohippuric Acid (PAH)

2)

Sodium Hydroxide (NaOH)
(Fisher Scientific Co., cat # S-318)

(Eastman Kodak Corp., cat. # 5704)

Dissolve each reagent separately in Physiological Sterile
Saline (PSS):

44.8 g PAH
10.5 g NaOH

Then add NaOH solution to PAH solution and stir.

May have to

heat gently to fully dissolve.
Filter through Whatman #4
filter paper. Titrate filtrate to pH 7.4 with 1 N HCl or 4 M
NaOH. Bring final volume to 500 ml. Yields a 1.5% solution
of sodium salt.
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